Biogen's Aduhelm Marketing and Approval are Under Scrutiny in New FTC and SEC Investigations
Biogen can't seem to get a break when it comes to the Alzheimer's disease drug Aduhelm. Along with limited sales and a constraining Medicare coverage plan, the medicine is now facing additional scrutiny as part of a pair of US government investigations.
The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have opened separate inquiries into Biogen and its troublesome Alzheimer's drug.
The Federal Trade Commission has issued a civil investigative demand, which is similar to an administrative subpoena, for records connected to Aduhelm's ma...
